ESMO: European Society for Medical Oncology

The latest news from ESMO
  1. New indication concerns a combination with gemcitabine and cisplatin in first-line treatment

  2. Updated indication restricts the use to patients whose tumours express PD-L1 CPS ≥ 1 as determined by an FDA-approved test

  3. The ESMO Immuno-Oncology Congress 2023, where experts discuss the latest scientific developments in this fast-moving field of cancer treatment, will be held in Geneva, Switzerland, between 6-8 December, also with a virtual component

  4. Findings from the FLAURA2 study

  5. Findings from the European MCL Elderly study